Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study.
Trecourt A, Bakrin N, Glehen O, Gertych W, Villeneuve L, Isaac S, Benzerdjeb N, Fontaine J, Genestie C, Dartigues P, Leroux A, Quenet F, Marchal F, Odin C, Khellaf L, Svrcek M, Thierry S, Augros M, Omar A, Devouassoux-Shisheboran M, Kepenekian V; RENAPE Group.
Imaging in pleural Mesothelioma: A review of the 16th International Conference of the International Mesothelioma Interest Group.
Armato SG 3rd, Katz SI, Frauenfelder T, Jayasekera G, Catino A, Blyth KG, Theodoro T, Rousset P, Nackaerts K, Opitz I.
CT venography for the diagnosis of postpartum venous thromboembolism: a prospective multi-center cohort study.
Revel MP, Chassagnon G, Sanchez O, Ferretti G, Millet I, Rocher L, Maitre S, Lederlin M, Ducou-le-Pointe H, Rousset P, Bennani S, Zins M, Bruneau B, Tissot V, Alison M, Canniff E, Siauve N, Vandeventer S, Le Blanche AF, Planquette B, Tsatsaris V, Coste J.
Correction: Diagnostic MRI for deep pelvic endometriosis: towards a standardized protocol?
Thomassin-Naggara I, Zoua CS, Bazot M, Monroc M, Roman H, Razakamanantsoa L, Rousset P; ENDOVALIRM study group.
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladieff L, Lamuraglia M.
Correlation of Morphological Appearance of Peritoneal Lesions at Laparotomy and Disease at Pathological Assessment in Patients Undergoing Cytoreductive Surgery for Peritoneal Malignancy: Results of Phase I of the PRECINCT Study in 707 Patients.
Bhatt A, Villeneuve L, Sardi A, Souadka A, Buseck A, Moran BJ, Khannousi BE, de Pedro CG, Baratti D, Biacchi D, Morris D, Labow D, Levine EA, Mohamed F, Adeleke G, Goswami G, Bonnefoy I, Perry KC, Votanopoulos KI, Parikh L, Deraco M, Alyami M, Cohen N, Benzerdjeb N, Shah N, Bahaoui NE, Khajoueinejad N, Rousset […]
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary.
González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O’Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ.
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladieff L, Lamuraglia M.
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Freyer G, Martinez-Jañez N, Kukielka-Budny B, Ulanska M, Bourgeois H, Muñoz M, Morales S, Calero JB, Cortesi L, Pintér T, Palácová M, Cherciu N, Petru E, Ettl J, de Almeida C, Villanova G, Raymond R, Minh CTT, Rodrigues A, Cazzaniga ME.
Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence.
Fasching PA, Kreipe H, Del Mastro L, Ciruelos E, Freyer G, Korfel A, Chouaki N, Stoffregen C, Sapunar F, Cameron D.
Hyperthermic intraperitoneal chemotherapy in colorectal cancer.
Fisher OM, Brown C, Esquivel J, Larsen SG, Liauw W, Alzahrani NA, Morris DL, Kepenekian V, Sourrouille I, Dumont F, Tuech JJ, Ceribelli C, Doussot B, Sgarbura O, Alhosni M, Quenet F, Glehen O, Cashin PH; Peritoneal Surface Oncology Group International (PSOGI), Nordic Peritoneal Oncology Group (NPOG), American Society for Peritoneal Surface Malignancy (ASPSM) and […]
Endometriosis MR mimickers: T2-hypointense lesions.
Ruaux E, VanBuren WM, Nougaret S, Gavrel M, Charlot M, Grangeon F, Bolze PA, Thomassin-Naggara I, Rousset P.